Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J L ADAMS

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Journal of Medicinal Chemistry|December 20, 1996
Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)ureaJ L Adams, R S Garigipati, M Sorenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2001
Measuring the incremental cost of clinical cancer researchD P Goldman, M L Schoenbaum, A L Potosky, et al.
The Journal of Biological Chemistry|May 2, 1997
Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP siteP R Young, M M McLaughlin, S Kumar, et al.
Medicinal Research Reviews|February 27, 2001
Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemiaF C Barone, E A Irving, A M Ray, et al.
Circulation|September 12, 2001
Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunctionT M Behr, S S Nerurkar, A H Nelson, et al.
Journal of Medicinal Chemistry|September 27, 1996
1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potencyJ C Boehm, J M Smietana, M E Sorenson, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemiaF C Barone, E A Irving, A M Ray, et al.
Nature|December 22, 1994
A protein kinase involved in the regulation of inflammatory cytokine biosynthesisJ C Lee, J T Laydon, P C McDonnell, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 9, 2001
Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal modelsR S Ames, D Lee, J J Foley, et al.
Bioorganic & Medicinal Chemistry|January 1, 1997
Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinaseT F Gallagher, G L Seibel, S Kassis, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Journal of Medicinal Chemistry|December 20, 1996
Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)ureaJ L Adams, R S Garigipati, M Sorenson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2001
Measuring the incremental cost of clinical cancer researchD P Goldman, M L Schoenbaum, A L Potosky, et al.
The Journal of Biological Chemistry|May 2, 1997
Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP siteP R Young, M M McLaughlin, S Kumar, et al.
Medicinal Research Reviews|February 27, 2001
Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemiaF C Barone, E A Irving, A M Ray, et al.
Circulation|September 12, 2001
Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunctionT M Behr, S S Nerurkar, A H Nelson, et al.
Journal of Medicinal Chemistry|September 27, 1996
1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potencyJ C Boehm, J M Smietana, M E Sorenson, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemiaF C Barone, E A Irving, A M Ray, et al.
Nature|December 22, 1994
A protein kinase involved in the regulation of inflammatory cytokine biosynthesisJ C Lee, J T Laydon, P C McDonnell, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 9, 2001
Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal modelsR S Ames, D Lee, J J Foley, et al.
Bioorganic & Medicinal Chemistry|January 1, 1997
Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinaseT F Gallagher, G L Seibel, S Kassis, et al.
Pageof 10